Diopsys Inc., a technology firm that has made unprecedented progress in the field of visual electrophysiology, said Wednesday that it relocating to expanded headquarters in Cedar Knolls.
A new 17,000-square-foot facility will provide additional space for operations, research & development laboratories, warehouse and manufacturing capabilities.
Diopsys became a wholly owned subsidiary of LumiThera Inc. three months ago. The acquisition created a complementary diagnosis and monitoring platform for LumiThera’s leading treatment platform. Diopsys has an established commercial U.S. sales force that will combine with LumiThera’s EU sales team to serve a large, global footprint of eye care professionals.
“The new East Coast operations center will aid the global expansion of the combined theranostic platforms,” Matt Emmer, vice president, medical affairs, Diopsys, said. “The theranostic company is focused on providing tools eye care professionals need to diagnose, treat and monitor patients, to deliver a solution for multiple ocular diseases with limited treatment options.”
“We are excited to expand operations in New Jersey as we rebrand the Diopsys diagnostic devices and work to bring Valeda therapy into the U.S. market,” Clark Tedford, CEO and president, LumiThera, said. “The new facilities provide us with the opportunity to broaden our research & development activities and create a pipeline of first-in-class products that can be used to address degenerative eye diseases early.”